Zomedica Corp.
- ZOMDF · OTC
- Pharmaceutical Preparations
- Ann Arbor, MI
- 141 employees
- CIK 0001684144
Updated from SEC filings through
Top things to know
Executives
- Larry Heaton Chief Executive Officer of Zomedica 8-K, 2026-11-04
- Larry C. Heaton Ii CEO 4, 2026-05-08
- Michael Zuehlke Vice President of Finance and Corporate Controller (Principal Financial and Accounting Officer) 10-Q, 2026-11-04
- Russell Kevin Klass Sr Vice President, Sales 4, 2026-08-07
- Karen DeHaan-Fullerton General Counsel 4, 2026-08-07
- Anthony K. Blair COO 4, 2026-08-07
What leadership is saying
“Zomedica delivered record third quarter revenue, continued year-over-year growth across our business, and made further progress in managing and improving upon operating costs and cash consumption”
Earnings press release (8-K Ex. 99.1), filed November 4, 2026
Zomedica Corp. is a U.S. public company in pharmaceutical preparations (SIC 2834), headquartered in Ann Arbor, MI. It trades as ZOMDF on OTC. Revenue was $32.0M in the fiscal year ending December 31, 2025, +17.4% from the year before. It reported about 141 employees. Larry Heaton is Chief Executive Officer of Zomedica.
Five-year financials
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $32.0M 10-K, 2026-03-16 | $27.3M 10-K, 2026-03-16 | $25.2M 10-K, 2025-03-13 | $18.9M 10-K, 2024-04-01 | $4.1M 10-K, 2022-03-01 |
| Operating income | -$84.4M 10-K, 2026-03-16 | -$51.1M 10-K, 2026-03-16 | -$43.3M 10-K, 2025-03-13 | -$21.9M 10-K, 2024-04-01 | -$21.4M 10-K, 2023-03-15 |
| SG&A | $43.0M 10-K, 2026-03-16 | $46.8M 10-K, 2026-03-16 | $43.2M 10-K, 2025-03-13 | $33.0M 10-K, 2023-03-15 | $22.8M 10-K, 2023-03-15 |
| Net income | -$81.9M 10-K, 2026-03-16 | -$47.0M 10-K, 2026-03-16 | -$34.5M 10-K, 2025-03-13 | -$17.0M 10-K, 2024-04-01 | -$18.4M 10-K, 2023-03-15 |
Annual figures from XBRL in each company's own filings. Click a figure to open the filing. SG&A marked derived is general and administrative plus selling and marketing.
Leadership and board
| Name | Title | Source |
|---|---|---|
| Larry Heaton | Chief Executive Officer of Zomedica | 8-K, 2026-11-04 |
| Larry C. Heaton Ii Medical Device & Diagnostics Leader | CEO | 4, 2026-05-08 |
| Michael Zuehlke | Vice President of Finance and Corporate Controller (Principal Financial and Accounting Officer) | 10-Q, 2026-11-04 |
| Russell Kevin Klass | Sr Vice President, Sales | 4, 2026-08-07 |
| Karen DeHaan-Fullerton General Counsel at Zomedica | General Counsel | 4, 2026-08-07 |
| Anthony K. Blair | COO | 4, 2026-08-07 |
| Chris MacLeod | Director | 10-K, 2026-03-16 |
| Jeffrey Rowe | Director | 10-K, 2026-03-16 |
| Johnny D. Powers | Director | 10-K, 2026-03-16 |
| Robert Cohen | Director | 10-K, 2026-03-16 |
| Rodney Williams | Director | 10-K, 2026-03-16 |
What Zomedica Corp. does
Zomedica Corp. (“Zomedica” or the “Company”) was incorporated on January 7, 2013 under the Business Corporations Act (Alberta) as Wise Oakwood Ventures Inc.4 of the TSX Venture Exchange. ZoMedica Pharmaceuticals Inc. (“ZoMedica”) was incorporated on May 14, 2015, under the Canada Business Corporations Act.
Item 1. Business, 10-K for the year ending December 31, 2025
Shares and governance
| Shares outstanding | 979.9 million (as of November 4, 2026) | 10-Q, November 4, 2026 |
|---|---|---|
| Public float | $38.3M (as of June 30, 2025) | 10-K, March 16, 2026 |
| Reportable segments | 3 (period ending September 30, 2026) | 10-Q, November 4, 2026 |
| Latest proxy statement | Meeting April 24, 2026 (filed April 27, 2026) | DEF 14A, April 27, 2026 |
| Auditor | Grant Thornton LLP (Southfield, Michigan) | Latest 10-K |
Insider trades
Open-market buys and sales by officers and directors, from Forms 4 and 5. One row per filing.
| Date | Insider | Trade | Shares | Value | Source |
|---|---|---|---|---|---|
| May 21, 2026 | Russell Kevin Klass Sr. Vice President, Sales | Buy | 104,000 | $10K | Form 4, May 26, 2026 |
| May 20, 2026 | Johnny D. Powers Director | Buy | 200,000 | $20K | Form 4, May 21, 2026 |
| May 13, 2026 | Johnny D. Powers Director | Buy | 300,000 | $33K | Form 4, May 14, 2026 |
| May 11, 2026 | Johnny D. Powers Director | Buy | 500,000 | $55K | Form 4, May 11, 2026 |
| May 8, 2026 | Larry C. Heaton Ii CEO | Buy | 250,000 | $28K | Form 4, May 8, 2026 |
| November 13, 2025 | Russell Kevin Klass Sr Vice President, Sales | Buy | 150,000 | $15K | Form 4, November 14, 2025 |
| November 10, 2025 | Russell Kevin Klass Sr Vice President, Sales | Buy | 120,000 | $12K | Form 4, November 12, 2025 |
| November 7, 2025 | Russell Kevin Klass Sr Vice President, Sales | Buy | 5,000 | $500 | Form 4, November 10, 2025 |
Recent 8-K events
- 8-K filed 2026-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-08-05
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-06-11
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2026-05-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2026-03-16
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-11-04
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-08-06
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-06-11
- Item 5.07 Submission of matters to a vote of security holders
- 8-K filed 2025-05-15
- Item 2.02 Results of operations and financial condition (earnings release)
- 8-K filed 2025-04-30
- Item 5.02 Departure or appointment of directors or officers; compensation
Frequently asked questions about Zomedica Corp.
- What does Zomedica Corp. do?
- In its own words, from Item 1 of its 10-K: "Zomedica Corp. (“Zomedica” or the “Company”) was incorporated on January 7, 2013 under the Business Corporations Act (Alberta) as Wise Oakwood Ventures Inc.4 of the TSX Venture Exchange. ZoMedica Pharmaceuticals Inc. (“ZoMedica”) was incorporated on May 14, 2015, under the Canada Business Corporations Act."
- What is Zomedica Corp.'s revenue?
- $32.0M for the fiscal year ending December 31, 2025, from its 10-K filed March 16, 2026.
- Is Zomedica Corp. profitable?
- Zomedica Corp. reported net income of -$81.9M for the fiscal year ending December 31, 2025.
- How many employees does Zomedica Corp. have?
- About 141 as of December 31, 2025, as stated in its annual report.
- Who is the CEO of Zomedica Corp.?
- Larry Heaton, Chief Executive Officer of Zomedica, as named in a 8-K filed November 4, 2026.
- Where is Zomedica Corp. headquartered?
- Ann Arbor, MI.
- What is Zomedica Corp.'s stock ticker?
- ZOMDF on OTC.
- What industry is Zomedica Corp. in?
- Pharmaceutical Preparations, SIC code 2834.
- What is Zomedica Corp.'s website?
- zomedica.com. Investor relations: https://investors.zomedica.com.
- When does Zomedica Corp. report earnings next?
- November 20, 2026 at 16:00. Source: sec_8k.
- Is Zomedica Corp. a public company?
- Yes. Zomedica Corp. files with the SEC under CIK 0001684144 and trades as ZOMDF.
- Who audits Zomedica Corp.?
- Grant Thornton LLP, Southfield, Michigan, as named in its latest annual report (10-K).
- How many shares of Zomedica Corp. are outstanding?
- 979.9 million shares as of November 4, 2026, from its 10-Q filed November 4, 2026.
- What is Zomedica Corp.'s public float?
- $38.3M as of June 30, 2025, as reported on the cover of its 10-K filed March 16, 2026.
- How many business segments does Zomedica Corp. report?
- 3 reportable segments for the period ending September 30, 2026, from its 10-Q filed November 4, 2026.
- When is Zomedica Corp.'s annual shareholder meeting?
- April 24, 2026, per its proxy statement (DEF 14A) filed April 27, 2026.
- Have Zomedica Corp. insiders traded stock recently?
- Since August 8, 2025, officers and directors reported 0 open-market sales and 12 purchases worth about $276K on Forms 4 and 5. The most recent: Russell Kevin Klass (Sr. Vice President, Sales) bought 104,000 shares on May 21, 2026.